Letter by Al-Ruzzeh and Navia regarding article, "Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery".
Al-Ruzzeh
Sharif
S
Navia
Jose L
JL
D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D015415:Biomarkers; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D015986:Confounding Factors, Epidemiologic; D015942:Factor VIIa / Q000627:therapeutic use*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D010949:Plasma; D017713:Platelet Transfusion / Q000706:statistics & numerical data; D019106:Postoperative Hemorrhage / Q000188:drug therapy* / Q000628:therapy; D016032:Randomized Controlled Trials as Topic / Q000379:methods* / Q000706:statistics & numerical data; D011994:Recombinant Proteins / Q000627:therapeutic use; D012086:Reoperation / Q000706:statistics & numerical data; D012107:Research Design
D000933:Antifibrinolytic Agents; D015415:Biomarkers; D006490:Hemostatics; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa